论文部分内容阅读
卵巢癌是死亡率最高的妇科恶性肿瘤,在女性癌症死因中居第5位。近年来手术方式和化疗方案的改进一定程度上延长了卵巢癌患者的生存期,但是总体预后还是比较差。因此需要迫切寻求卵巢癌表达特异性高的生物标记物,以便更好地早期诊断和早期治疗,从而有效地改善卵巢癌患者的结局。实现这个目标,合适的临床前研究平台必不可少,这个平台需要综合这些肿瘤的复杂性并在临床中可靠地评估抗肿瘤作用。本综述将会展示包括异种移植模型,患者源性异种移植模型和基因工程鼠模型在内的卵巢癌临床前模型的研究现状和进展。
Ovarian cancer is the highest mortality rate of gynecological malignancies, the fifth highest risk of cancer in women. In recent years, the improvement of surgical methods and chemotherapy regimens to some extent extend the survival of patients with ovarian cancer, but the overall prognosis is still relatively poor. Therefore, it is necessary to urgently look for specific biomarkers of ovarian cancer for better early diagnosis and early treatment, so as to effectively improve the outcome of ovarian cancer patients. To achieve this goal, a suitable preclinical research platform is essential, and the platform needs to integrate the complexities of these tumors and reliably evaluate the anti-tumor effects clinically. This review will present the current status and advances in the development of preclinical ovarian cancer models including xenograft models, patient-derived xenograft models, and genetically engineered mouse models.